CAR-T cells for H3K27-altered diffuse midline gliomas: where do we stand?
作者信息
Power Erica A, Millesi Elena, Rechberger Julian S, Daniels David J
机构信息
Loyola University Chicago Stritch School of Medicine, Maywood, IL 60141, USA.
Division of Plastic & Reconstructive Surgery, Department of Surgery, Mayo Clinic, Rochester, MN 55905, USA.
出版信息
Immunotherapy. 2024;16(12):775-778. doi: 10.1080/1750743X.2024.2373043. Epub 2024 Jul 17.
Abstract
摘要
相似文献
1
CAR-T cells for H3K27-altered diffuse midline gliomas: where do we stand?用于H3K27改变的弥漫性中线胶质瘤的嵌合抗原受体T细胞：我们目前的进展如何？
Immunotherapy. 2024;16(12):775-778. doi: 10.1080/1750743X.2024.2373043. Epub 2024 Jul 17.
2
Intravenous and intracranial GD2-CAR T cells for H3K27M diffuse midline gliomas.用于H3K27M弥漫性中线胶质瘤的静脉内和颅内GD2嵌合抗原受体T细胞
Nature. 2025 Jan;637(8046):708-715. doi: 10.1038/s41586-024-08171-9. Epub 2024 Nov 13.
3
IL-13Rα2-targeted CAR T cells show promise in patients with recurrent high-grade gliomas.靶向白细胞介素-13受体α2的嵌合抗原受体T细胞在复发性高级别胶质瘤患者中显示出前景。
Nat Rev Clin Oncol. 2024 May;21(5):335. doi: 10.1038/s41571-024-00885-z.
4
CAR T-cell therapy: a potential treatment strategy for pediatric midline gliomas.嵌合抗原受体 T 细胞疗法：小儿中线胶质瘤的一种潜在治疗策略。
Acta Neurol Belg. 2024 Aug;124(4):1251-1261. doi: 10.1007/s13760-024-02519-8. Epub 2024 Apr 26.
5
Genetically Engineered T-Cells for Malignant Glioma: Overcoming the Barriers to Effective Immunotherapy.基因工程 T 细胞治疗恶性脑胶质瘤：克服免疫治疗的障碍。
Front Immunol. 2019 Jan 22;9:3062. doi: 10.3389/fimmu.2018.03062. eCollection 2018.
6
Potent antitumor efficacy of anti-GD2 CAR T cells in H3-K27M diffuse midline gliomas.抗 GD2 CAR T 细胞在 H3-K27M 弥漫性中线脑胶质瘤中的强大抗肿瘤疗效。
Nat Med. 2018 May;24(5):572-579. doi: 10.1038/s41591-018-0006-x. Epub 2018 Apr 16.
7
Clinical progress in the development of CAR T cells to treat malignant glioma.用于治疗恶性胶质瘤的嵌合抗原受体T细胞（CAR T细胞）的临床进展。
J Neurooncol. 2025 Feb;171(3):571-579. doi: 10.1007/s11060-024-04909-7. Epub 2024 Dec 18.
8
GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas.用于 H3K27M 突变型弥漫性中线脑胶质瘤的 GD2-CAR T 细胞疗法。
Nature. 2022 Mar;603(7903):934-941. doi: 10.1038/s41586-022-04489-4. Epub 2022 Feb 7.
9
EphA3-targeted chimeric antigen receptor T cells are effective in glioma and generate curative memory T cell responses.EphA3 靶向嵌合抗原受体 T 细胞在神经胶质瘤中有效，并产生治愈性记忆 T 细胞反应。
J Immunother Cancer. 2024 Aug 7;12(8):e009486. doi: 10.1136/jitc-2024-009486.
10
Chimeric antigen receptor T-cell therapy in patients with malignant glioma-From neuroimmunology to clinical trial design considerations.恶性胶质瘤患者的嵌合抗原受体T细胞疗法——从神经免疫学到临床试验设计考量
Neuro Oncol. 2025 Feb 10;27(2):352-368. doi: 10.1093/neuonc/noae203.
本文引用的文献
1
CAR T-cell Design-dependent Remodeling of the Brain Tumor Immune Microenvironment Modulates Tumor-associated Macrophages and Anti-glioma Activity.CAR T 细胞设计依赖性重塑脑肿瘤免疫微环境调节肿瘤相关巨噬细胞和抗神经胶质瘤活性。
Cancer Res Commun. 2023 Dec 1;3(12):2430-2446. doi: 10.1158/2767-9764.CRC-23-0424.
2
Bench-to-bedside investigations of H3 K27-altered diffuse midline glioma: drug targets and potential pharmacotherapies.H3 K27 改变弥漫性中线脑胶质瘤的从 bench 到 bedside 研究：药物靶点和潜在的药物治疗方法。
Expert Opin Ther Targets. 2023 Jul-Dec;27(11):1071-1086. doi: 10.1080/14728222.2023.2277232. Epub 2023 Dec 7.
3
B7-H3 in Brain Malignancies: Immunology and Immunotherapy.B7-H3 在脑恶性肿瘤中的作用：免疫学和免疫治疗。
Int J Biol Sci. 2023 Jul 24;19(12):3762-3780. doi: 10.7150/ijbs.85813. eCollection 2023.
4
CAR T cell therapies for diffuse midline glioma.嵌合抗原受体 T 细胞疗法治疗弥漫性中线胶质瘤。
Trends Cancer. 2023 Oct;9(10):791-804. doi: 10.1016/j.trecan.2023.07.007. Epub 2023 Aug 3.
5
CAR immune cells: design principles, resistance and the next generation.嵌合抗原受体（CAR）免疫细胞：设计原理、抗性与下一代产品
Nature. 2023 Feb;614(7949):635-648. doi: 10.1038/s41586-023-05707-3. Epub 2023 Feb 22.
6
Immune Microenvironment and Immunotherapies for Diffuse Intrinsic Pontine Glioma.弥漫性脑桥内在型胶质瘤的免疫微环境与免疫疗法
Cancers (Basel). 2023 Jan 18;15(3):602. doi: 10.3390/cancers15030602.
7
Intraventricular B7-H3 CAR T Cells for Diffuse Intrinsic Pontine Glioma: Preliminary First-in-Human Bioactivity and Safety.脑室注射 B7-H3 CAR T 细胞治疗弥漫内生型脑桥胶质瘤：初步人体首用的生物活性和安全性。
Cancer Discov. 2023 Jan 9;13(1):114-131. doi: 10.1158/2159-8290.CD-22-0750.
8
GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas.用于 H3K27M 突变型弥漫性中线脑胶质瘤的 GD2-CAR T 细胞疗法。
Nature. 2022 Mar;603(7903):934-941. doi: 10.1038/s41586-022-04489-4. Epub 2022 Feb 7.
9
CAR-T cell therapy: current limitations and potential strategies.嵌合抗原受体 T 细胞疗法：当前的局限性和潜在策略。
Blood Cancer J. 2021 Apr 6;11(4):69. doi: 10.1038/s41408-021-00459-7.
10
CAR-T design: Elements and their synergistic function.CAR-T 设计：要素及其协同功能。
EBioMedicine. 2020 Aug;58:102931. doi: 10.1016/j.ebiom.2020.102931. Epub 2020 Jul 30.
Zotero 插件